Coronavirus is the newfound evil whose demolition is the most important conquest of every scientist for the time being. The exact vaccine or drug which is effective has not been discovered till now and researchers are sweating out to find the right medicine that affects the type of protein that this particular virus is targeting and affecting leading to immediate collapse and requirement for treatment. Meanwhile, Northeastern University’s network scientists have worked together to identify forty new drugs against the virus in an effort to help the global scientific community to resolve the coronavirus crisis.
Northeastern University has joined hands with the experimental biologists at Harvard University to test these drugs in the human line to declare its effectiveness to treat the SARS-CoV-2, the new coronavirus. The leading man of this research is Albert-László Barabási, Robert Gray Dodge Professor of Network Science and University Distinguished Professor of Physics at Northeastern, who with his team has experimented with a modelling tool for infection dynamics based on network science to discover many more drugs; however, they have prioritised forty amongst them.
Barabási says, “Virtually every disease that we have spreads through a cellular network,” and this virus has particularly a speedy method of invading the human cells with 26 proteins to execute an effective perturbation in the call network of the human body. He also says that to understand the nature of the viruses, we should also consider the whole set of molecular interactions of human cells and read the neighbourhood proteins as well.
The 2012 model which Barabási developed to study other human viruses also predicted the early symptoms of the SARS-CoV-19 which attacks the cell in the human brain and the new model has focused on drugs that could neutralise its spike proteins and also disrupt the other interactions with human protein and genes. These findings are believed to be infallible to help in the global medical scenario as Barabási says, “There is such an imminent need to make progress in this area, that we cannot be slaves of our existing academic or business models.”